Moderna, Inc. (FRA:0QF)
| Market Cap | 8.37B |
| Revenue (ttm) | 1.90B |
| Net Income (ttm) | -2.66B |
| Shares Out | n/a |
| EPS (ttm) | -6.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 283 |
| Average Volume | 56,366 |
| Open | 20.89 |
| Previous Close | 20.58 |
| Day's Range | 20.25 - 21.21 |
| 52-Week Range | 19.89 - 54.20 |
| Beta | n/a |
| RSI | 45.06 |
| Earnings Date | Nov 6, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Notable healthcare headlines for the week: Pfizer, Novo Nordisk, Moderna in focus
Moderna, Inc. 2025 Q3 - Results - Earnings Call Presentation
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street esti...
Moderna (MRNA) Reports Q3 Revenue and Strategic Developments
Moderna (MRNA) Reports Q3 Revenue and Strategic Developments
Moderna lowers 2025 cash cost guidance by $900M while advancing late-stage pipeline
Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript
Moderna, Inc. (MRNA) Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsLavina Talukdar - Senior VP & Head of Investor...
Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue ...
Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue Challenges
Q3 2025 Moderna Inc Earnings Call Transcript
Q3 2025 Moderna Inc Earnings Call Transcript
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
Moderna Inc. (NASDAQ: MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02 , a turnaround from an income of 3 cents a year ago. MRNA stock is racing ahead of the pack. ...
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.
Moderna Q3 2025 Earnings Call Transcript
Moderna, Inc (NASDAQ: MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. MRNA is building positive mome...
Investor Outlook: Moderna posts stronger Q3 as cost-cutting cushions weaker COVID vaccine sales
Moderna beats Q3 forecasts as cost-cutting offsets weaker COVID vaccine sales and new mRNA cancer trials advance.
Moderna begins trails in cancer treatment vaccine
Geoff Meacham, managing director, biotech & pharma equity research at Citi, joins BNN Bloomberg to discuss Moderna's Q3 earnings.
Moderna’s Quarter Wasn’t As Bad as It Could Have Been. The Stock Is Up.
Moderna Posts Loss In Q3
(RTTNews) - Moderna (MRNA) posted a third-quarter net loss of $200 million compared to net income of $13 million, last year. Loss per share was $0.51 compared to profit of $0.03. Analysts on average e...
Moderna Surges; Covid Vaccine Sales Decline, But Top Expectations
Moderna stock surged Thursday. Though third-quarter vaccine sales declined, they came in above expectations.
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of +76.28% and +18.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Surpasses Earnings and Revenue Expectations
Moderna (MRNA) Surpasses Earnings and Revenue Expectations
Moderna (MRNA) Surpasses Q3 Revenue Forecasts Despite Decline
Moderna (MRNA) Surpasses Q3 Revenue Forecasts Despite Decline
Moderna (MRNA) Projects Lower Cost of Sales for 2025
Moderna (MRNA) Projects Lower Cost of Sales for 2025
Moderna (MRNA) Reports Strong Q3 Revenue Boosted by COVID Vaccine Sales
Moderna (MRNA) Reports Strong Q3 Revenue Boosted by COVID Vaccine Sales
Moderna posts Q3 beat even as weak vaccine sales drive revenue slump
Moderna Inc (MRNA) Q3 2025 Earnings: EPS of $(0. ...
Moderna Inc (MRNA) Q3 2025 Earnings: EPS of $(0.51) Beats Estimate, Revenue Surpasses Expectations at $1.0 Billion
Earnings Snapshot: Moderna tops Q3, guides FY revenue below consensus after 47% COVID-19 vaccine sales drop
Moderna trims top end of full-year forecast on weak COVID vaccine sales
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots.